2. Le V V H, Davies I G, Moon C D, Wheeler D, Biggs P J, Rakonjac J. (2019). Novel 5-
nitrofuran-activating reductase in Escherichia coli.
Antimicrobial agents and chemotherapy, 63(11): e00868-00819.
[
Crossref], [
Google Scholar], [
Publisher]
3. Kamal A, Hussaini S M A, Faazil S, Poornachandra Y, Reddy G N, Kumar C G, Rajput V S,
Rani C, Sharma R, Khan I A. (2013). Anti-tubercular agents. Part 8: Synthesis,
antibacterial and antitubercular activity of 5-nitrofuran based 1, 2, 3-triazoles.
Bioorganic & Medicinal Chemistry Letters, 23(24): 6842-6846. [
Crossref], [
Google Scholar], [
Publisher]
4. Liberati A, Altman D G, Tetzlaff J, Mulrow C, Gøtzsche P C, Ioannidis J P A, Clarke M,
Devereaux P J, Kleijnen J, Moher D. (2009). The PRISMA statement for reporting
systematic reviews and meta-analyses of studies that evaluate health care
interventions: explanation and elaboration.
J Clin Epidemiol, 62(10): e1-e34.
[
Crossref], [
Google Scholar], [
Publisher]
5. Krasavin M, Lukin A, Vedekhina T, Manicheva O, Dogonadze M, Vinogradova T,
Zabolotnykh N, Rogacheva E, Kraeva L, Sharoyko V. (2019). Attachment of a 5-
nitrofuroyl moiety to spirocyclic piperidines produces non-toxic nitrofurans that are
efficacious in vitro against multidrug-resistant Mycobacterium tuberculosis.
European journal of medicinal chemistry, 166: 125-135.
[
Crossref], [
Google Scholar], [
Publisher]
6. Gallardo-Macias R, Kumar P, Jaskowski M, Richmann T, Shrestha R, Russo R, Singleton E,
Zimmerman M D, Ho H P, Dartois V. (2019). Optimization of N-benzyl-5-nitrofuran-2-
carboxamide as an antitubercular agent.
Bioorganic & Medicinal Chemistry Letters,
29(4): 601-606.
[
Crossref], [
Google Scholar], [
Publisher]
7. Pandolfi F, D'Acierno F, Bortolami M, De Vita D, Gallo F, De Meo A, Di Santo R, Costi R,
Simonetti G, Scipione L. (2019). Searching for new agents active against Candida
albicans biofilm: A series of indole derivatives, design, synthesis and biological
evaluation.
European Journal of Medicinal Chemistry, 165: 93-106. [
Crossref], [
Google Scholar], [
Publisher]
8. Fan Y-L, Wu J-B, Ke X, Huang Z-P. (2018). Design, synthesis and evaluation of oxime-
functionalized nitrofuranylamides as novel antitubercular agents.
Bioorganic & Medicinal Chemistry Letters, 28(18): 3064-3066.
[
Crossref], [
Google Scholar], [
Publisher]
9. Phillips O A, Udo E E, D’silva R J. (2018). Structure-Antibacterial Activity Relationships of
N-Substituted-(D-/L-Alaninyl) 1H-1, 2, 3-Triazolylmethyl Oxazolidinones.
Scientia pharmaceutica, 86(4): 42.
[
Crossref], [
Google Scholar], [
Publisher]
10. Krasavin M, Lukin A, Vedekhina T, Manicheva O, Dogonadze M, Vinogradova T,
Zabolotnykh N, Rogacheva E, Kraeva L, Yablonsky P. (2018). Conjugation of a 5-
nitrofuran-2-oyl moiety to aminoalkylimidazoles produces non-toxic nitrofurans that
are efficacious in vitro and in vivo against multidrug-resistant Mycobacterium
tuberculosis.
European journal of medicinal chemistry, 157: 1115-1126.
[
Crossref], [
Google Scholar], [
Publisher]
11. Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N, Kosiek K, De
Tejada B M, Roux X, Shiber S. (2018). Effect of 5-day nitrofurantoin vs single-dose
fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in
women: a randomized clinical trial.
Jama, 319(17): 1781-1789.
[
Crossref], [
Google Scholar], [
Publisher]
12. Roveri P, Cavrini V, Gatti R, Bianucci F, Legnani P. (1982). Synthesis and Antimicrobial
Activity of Some New 5‐Nitrofuran Derivatives.
Archiv der Pharmazie, 315(4): 330-333.
[
Crossref], [
Google Scholar], [
Publisher]
13. Picconi P, Prabaharan P, Auer J L, Sandiford S, Cascio F, Chowdhury M, Hind C, Wand
M E, Sutton J M, Rahman K M. (2017). Novel pyridyl nitrofuranyl isoxazolines show
antibacterial activity against multiple drug resistant Staphylococcus species.
Bioorganic & medicinal chemistry, 25(15): 3971-3979.
[
Crossref], [
Google Scholar], [
Publisher]
14. Verbitskiy E V, Baskakova S A, Natal'ya A G, Natal'Ya P E, Natal'Ya V, Kungurov N V,
Kravchenko M A, Skornyakov S N, Pervova M G, Rusinov G L. (2017). Synthesis and
biological evaluation of novel 5-aryl-4-(5-nitrofuran-2-yl)-pyrimidines as potential anti-
bacterial agents.
Bioorganic & Medicinal Chemistry Letters, 27(13): 3003-3006.
[
Crossref], [
Google Scholar], [
Publisher]
15. Arias D G, Herrera F E, Garay A S, Rodrigues D, Forastieri P S, Luna L E, Bürgi M,
Prieto C, Iglesias A A, Cravero R M. (2017). Rational design of nitrofuran derivatives:
Synthesis and valuation as inhibitors of Trypanosoma cruzi trypanothione reductase.
European Journal of Medicinal Chemistry, 125: 1088-1097.
[
Crossref], [
Google Scholar], [
Publisher]
16. Gould E R, King E F, Menzies S K, Fraser A L, Tulloch L B, Zacharova M K, Smith T K,
Florence G J. (2017). Simplifying nature: Towards the design of broad spectrum
kinetoplastid inhibitors, inspired by acetogenins.
Bioorganic & medicinal chemistry,
25(22): 6126-6136.
[
Crossref], [
Google Scholar], [
Publisher]
17. Ran K, Gao C, Deng H, Lei Q, You X, Wang N, Shi Y, Liu Z, Wei W, Peng C. (2016).
Identification of novel 2-aminothiazole conjugated nitrofuran as antitubercular and
antibacterial agents.
Bioorganic & Medicinal Chemistry Letters, 26(15): 3669-3674.
[
Crossref], [
Google Scholar], [
Publisher]
18. Abdel-Aziz H A-K, Eldehna W M, Fares M, Elsaman T, Abdel-Aziz M M, Soliman D H.
(2015). Synthesis, in vitro and in silico studies of some novel 5-nitrofuran-2-yl
hydrazones as antimicrobial and antitubercular agents.
Biological and Pharmaceutical Bulletin, 38: 1617-1630.
[
Crossref], [
Google Scholar], [
Publisher]
19. Pieroni M, Wan B, Zuliani V, Franzblau S G, Costantino G, Rivara M. (2015). Discovery
of antitubercular 2, 4-diphenyl-1H-imidazoles from chemical library repositioning and
rational design.
European journal of medicinal chemistry, 100: 44-49.
[
Crossref], [
Google Scholar], [
Publisher]
20. Samala G, Devi P B, Nallangi R, Sridevi J P, Saxena S, Yogeeswari P, Sriram D. (2014).
Development of novel tetrahydrothieno [2, 3-c] pyridine-3-carboxamide based
Mycobacterium tuberculosis pantothenate synthetase inhibitors: molecular
hybridization from known antimycobacterial leads.
Bioorganic & medicinal chemistry,
22(6): 1938-1947.
[
Crossref], [
Google Scholar], [
Publisher]
21. Zorzi R R, Jorge S D, Palace-Berl F, Pasqualoto K F M, de Sá Bortolozzo L, de Castro
Siqueira A M, Tavares L C. (2014). Exploring 5-nitrofuran derivatives against
nosocomial pathogens: synthesis, antimicrobial activity and chemometric analysis.
Bioorganic & medicinal chemistry, 22(10): 2844-2854.
[
Crossref], [
Google Scholar], [
Publisher]
22. Asadipour A, Edraki N, Nakhjiri M, Yahya-Meymandi A, Alipour E, Saniee P, Siavoshi F,
Shafiee A, Foroumadi A. (2013). Anti-Helicobacter pylori activity and structure-activity
relationship study of 2-alkylthio-5-(nitroaryl)-1, 3, 4-thiadiazole derivatives.
Iranian Journal of Pharmaceutical Research: IJPR, 12(3): 281.
[
Crossref], [
Google Scholar], [
Publisher]
23. Phillips O A, Udo E E, Abdel-Hamid M E, Varghese R. (2013). Synthesis and antibacterial
activities of N-substituted-glycinyl 1H-1, 2, 3-triazolyl oxazolidinones.
European journal of medicinal chemistry, 66: 246-257.
[
Crossref], [
Google Scholar], [
Publisher]
24. Lapa G B, Bekker O, Mirchink E, Danilenko V, Preobrazhenskaya M. (2013).
Regioselective acylation of congeners of 3-amino-1H-pyrazolo [3, 4-b] quinolines, their
activity on bacterial serine/threonine protein kinases and in vitro antibacterial
(including antimycobacterial) activity.
Journal of Enzyme Inhibition and Medicinal Chemistry, 28(5): 1088-1093.
[
Crossref], [
Google Scholar], [
Publisher]
25. Yanagita H, Fudo S, Urano E, Ichikawa R, Ogata M, Yokota M, Murakami T, Wu H, Chiba
J, Komano J. (2012). Structural modulation study of inhibitory compounds for
ribonuclease H activity of human immunodeficiency virus type 1 reverse transcriptase.
Chemical and Pharmaceutical Bulletin, 60(6): 764-771.
[
Crossref], [
Google Scholar], [
Publisher]
26. Badr S M, Barwa R M. (2011). Synthesis of some new [1, 2, 4] triazolo [3, 4-b][1, 3, 4]
thiadiazines and [1, 2, 4] triazolo [3, 4-b][1, 3, 4] thiadiazoles starting from 5-nitro-2-
furoic acid and evaluation of their antimicrobial activity.
Bioorganic & medicinal chemistry, 19(15): 4506-4512.
[
Crossref], [
Google Scholar], [
Publisher]
27. Soares de Oliveira C, dos Santos Falcão-Silva V, Siqueira-Júnior J P, Harding D P, Lira B
F, Lorenzo J G F, Barbosa-Filho J M, Filgueiras de Athayde-Filho P. (2011). Drug
resistance modulation in Staphylococcus aureus, a new biological activity for mesoionic
hydrochloride compounds.
Molecules, 16(3): 2023-2031.
[
Crossref], [
Google Scholar], [
Publisher]
28. Blackburn C, Duffey M O, Gould A E, Kulkarni B, Liu J X, Menon S, Nagayoshi M, Vos T J,
Williams J. (2010). Discovery and optimization of N-acyl and N-aroylpyrazolines as B-
Raf kinase inhibitors.
Bioorganic & Medicinal Chemistry Letters, 20(16): 4795-4799.
[
Crossref], [
Google Scholar], [
Publisher]
29. Kamal A, Shetti R V, Azeeza S, Ahmed S K, Swapna P, Reddy A M, Khan I A, Sharma S,
Abdullah S T. (2010). Anti-tubercular agents. Part 5: Synthesis and biological evaluation
of benzothiadiazine 1, 1-dioxide based congeners.
European journal of medicinal chemistry, 45(10): 4545-4553.
[
Crossref], [
Google Scholar], [
Publisher]
30. Ancizu S, Moreno E, Torres E, Burguete A, Pérez-Silanes S, Benítez D, Villar R, Solano B,
Marín A, Aldana I. (2009). Heterocyclic-2-carboxylic acid (3-cyano-1, 4-di-N-
oxidequinoxalin-2-yl) amide derivatives as hits for the development of neglected
disease drugs.
Molecules, 14(6): 2256-2272.
[
Crossref], [
Google Scholar], [
Publisher]
31. Al‐Saadi M S, Faidallah H M, Rostom S A. (2008). Synthesis and biological evaluation of
some 2, 4, 5‐trisubstituted thiazole derivatives as potential antimicrobial and anticancer
agents.
Arch. Pharm., 341(7): 424-434.
[
Crossref], [
Google Scholar], [
Publisher]
32. Kamal A, Ahmed S K, Reddy K S, Khan M N A, Shetty R V, Siddhardha B, Murthy U, Khan
I A, Kumar M, Sharma S. (2007). Anti-tubercular agents. Part IV: Synthesis and
antimycobacterial evaluation of nitroheterocyclic-based 1, 2, 4-benzothiadiazines.
Bioorganic & Medicinal Chemistry Letters, 17(19): 5419-5422.
[
Crossref], [
Google Scholar], [
Publisher]
33. Metwally K A, Abdel-Aziz L M, Lashine E-S M, Husseiny M I, Badawy R H. (2006).
Hydrazones of 2-aryl-quinoline-4-carboxylic acid hydrazides: Synthesis and
preliminary evaluation as antimicrobial agents.
Bioorganic & medicinal chemistry,
14(24): 8675-8682.
[
Crossref], [
Google Scholar], [
Publisher]
34. Ghannoum M, Thomson M, Beadlec C, Bowman W. (1988). Antibacterial activity of
some α-substituted 2-methyl-5-nitrofurans.
Folia microbiologica, 33(3): 198.
[
Crossref], [
Google Scholar], [
Publisher]
35. Jones Jr G S, Daly J S. (1993). Antibacterial organophosphorus compounds:
Phosphoranilidohydrazones of 5‐nitro‐2‐furaldehyde.
Journal of pharmaceutical sciences, 82(7): 755-757.
[
Crossref], [
Google Scholar], [
Publisher]
36. Kupchik E J, Pisano M A, Whalen S M, Lynch J. (1982). Synthesis and antimicrobial
activity of triorganotin 5‐nitro‐2‐furoates.
Journal of pharmaceutical sciences, 71(3):
311-314.
[
Crossref], [
Google Scholar], [
Publisher]
37. Chadfield M, Hinton M. (2003). Evaluation of treatment and prophylaxis with
nitrofurans and comparison with alternative antimicrobial agents in experimental
Salmonella enterica serovar Enteritidis infection in chicks.
Veterinary research communications, 27(4): 257-273.
[
Crossref], [
Google Scholar], [
Publisher]
38. Gadebusch H, Basch H. (1974). New Antimicrobial Nitrofuran, trans-5-Amino-3-[2-(5-
Nitro-2-Furyl) Vinyl]-Δ2-1, 2, 4-Oxadiazole: Antibacterial, Antifungal, and Antiprotozoal
Activities In Vitro.
Antimicrobial agents and chemotherapy, 6(3): 263-267.
[
Crossref], [
Google Scholar], [
Publisher]
39. McOsker C C, Fitzpatrick P M. (1994). Nitrofurantoin: mechanism of action and
implications for resistance development in common uropathogens.
J Antimicrob Chemother, 33 Suppl A: 23-30.
[
Crossref], [
Google Scholar], [
Publisher]
40. Karpman E, Kurzrock E A. (2004). Adverse reactions of nitrofurantoin, trimethoprim
and sulfamethoxazole in children.
J Urol., 172(2): 448-453.
[
Crossref], [
Google Scholar], [
Publisher]
)
)
